Appointments

Andrew joins Amylyx with over 30 years of life sciences’ industry experience, having spent a decade working on the commercialisaation of rare and specialised disease therapies in the UK and Ireland.

Previously, Andrew has worked at Orphazyme, Akcea Therapeutics, as well as formerly working as a commercial lead at Alexion Pharmaceutical and part of Merck Serono’s UK senior leadership team.

Stéphanie Hoffmann-Gendebien, head and generalmanagerEMEAatAmylyxPharmaceuticals, stated: “We are thrilled to have Andrew join us on our mission to end the suffering caused by neurodegenerative diseases. His unique experience and knowledge will help solidify our presence in the region, with the aim to build strong collaboration with the community to ensure people living with neurodegenerative disease can benefit from advances in care and therapeutic options in the UK and Ireland.”

Commenting on his new role, Andrew added: “As someone who has worked in the field of rare and ultra-rare diseases for over a decade, I’m deeply committed to supporting people who live with these devastating conditions and the wider community of people who care for them. Working as part of the Amylyx EMEA team, I’m determined to help advance our position in motor neurone disease, which has had no new treatment option in Europe for more than 25 years. Alongside this, I’m excited to be part of Amylyx’ progress in addressing other neurodegenerative diseases.”